TY - JOUR
AU - Nayak, Lakshmi
AU - Bettegowda, Chetan
AU - Scherer, Florian
AU - Galldiks, Norbert
AU - Ahluwalia, Manmeet
AU - Baraniskin, Alexander
AU - von Baumgarten, Louisa
AU - Bromberg, Jacoline E C
AU - Ferreri, Andrés J M
AU - Grommes, Christian
AU - Hoang-Xuan, Khê
AU - Kühn, Julia
AU - Rubenstein, James L
AU - Rudà, Roberta
AU - Weller, Michael
AU - Chang, Susan M
AU - van den Bent, Martin J
AU - Wen, Patrick Y
AU - Soffietti, Riccardo
TI - Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
JO - Neuro-Oncology
VL - 26
IS - 6
SN - 1522-8517
CY - Oxford
PB - Oxford Univ. Press
M1 - FZJ-2024-03594
SP - 993 - 1011
PY - 2024
AB - Background: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors.Methods: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)-liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL).Results: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome.Conclusions: Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.Keywords: CSF biomarkers; MYD88 mutations; circulating tumor DNA; primary CNS lymphomas; secondary CNS lymphomas
LB - PUB:(DE-HGF)16
C6 - 38598668
UR - <Go to ISI:>//WOS:001229686400001
DO - DOI:10.1093/neuonc/noae032
UR - https://juser.fz-juelich.de/record/1027028
ER -